Physician profile
Michael G Wade
NPI 1144243205
$1,312.77
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $353 · 2021: $353 · 2022: $309 · 2023: $75.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.74 | 2020-2022 | |
| Abbvie INC. | $108.26 | 2021-2022 | |
| Lucid Diagnostics INC. | $107.31 | 2021 | |
| Pfizer INC. | $105.44 | 2020-2021 | |
| Amgen INC. | $83.61 | 2019-2022 | |
| Boston Scientific Corporation | $77.61 | 2019-2023 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $76.19 | 2019-2022 | |
| Abbott Laboratories | $75.39 | 2019-2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.07 | 2019-2020 | |
| Lilly USA, LLC | $47.02 | 2020-2022 | |
| Eisai INC. | $41.76 | 2020 | |
| Strongbridge US INC. | $35.78 | 2020 | |
| Novo Nordisk INC | $35.14 | 2022 | |
| Horizon Therapeutics Plc | $30.51 | 2020-2021 | |
| Amarin Pharma, INC. | $25.37 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.25 | 2022 | |
| Genentech USA, INC. | $23.48 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.86 | 2022 | |
| Vertos Medical, INC. | $18.64 | 2023 | Mild Device Kit |
| Ironwood Pharmaceuticals, INC | $18.25 | 2020 | |
| Allergan, INC. | $17.49 | 2020 | |
| Glaxosmithkline, LLC. | $17.29 | 2020 | |
| Alfasigma USA, INC. | $16.92 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.50 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.21 | 2022 | |
| Therapeuticsmd, INC. | $13.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.37 | 2019 | |
| Neotract INC. | $11.86 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.34 | 2019 | |
| Medtronic USA, INC. | $11.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.